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In Spain, the first positive case of SARS-Cov-2 was diagnosed on 31 January 2020 in 
the Canary Islands and, as of 7 May 2020, there have been 221,447 cases, the most in 
any European Union country (1). The most common signs of infection are respiratory 
symptoms and the transmission of the virus before symptom onset is unclear.  Most 
initial clinical studies have been carried out in China and there are no studies in the 
Mediterranean population. This study aimed to describe the clinical, biological and 
radiological manifestations, the evolution, treatments and mortality rate of patients with 
COVID-19 infection in the population of Barcelona city. 
 
METHODS 
We made a multicenter observational descriptive study of the first COVID-19 patients 
diagnosed by polymerase chain reaction (PCR) in urban primary care centers serving an 
assigned population of 100,000, with the same reference hospital, in Barcelona city. All 
data were obtained from the medical record. Signs and symptoms, the main available 
haematological and biochemical data and the results of imaging tests were recorded, as 
were comorbidities, the evolution, the hospitalization rate, intensive care unit (ICU) 
admission and the treatments received. The study was conducted according to the 
Helsinki Declaration and Spanish legislation on biomedical studies, data protection and 
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We included 322 patients with a mean age of 56.7 years (standard deviation [SD] 17.8) 
of whom 50% were female and 115 (35.7%) were aged ≥ 65 years (Figure 1). The most 
frequent symptoms were cough (73.9%), fever (63.8%), general discomfort (43.5%), 
fatigue (30.7%), myalgia (30.1%), dyspnea (25.5%), diarrhea (23%), headache (20.8%), 
anosmia (17.4%) and dysgeusia (14.9%). Examination showed 69.1% had auscultatory 
alterations, 28.7% tachypnea and 20.5% an oxygen saturation of ≤ 92%. The most 
frequent comorbidities were hypertension (33.9%), diabetes mellitus (14.3%) obesity 
(14.3%). Chest X-rays was made in 227 (70.5%), chest CT in 28 (8.7%) and pulmonary 
ultrasound in 10 (3.1%). Radiologic findings showed lobar pulmonary infiltrates in 
15.8%, bilateral pulmonary infiltrates in 57.9% and an interstitial pattern in 24.1%. 
Analyses showed lymphopenia in 81.4%, LDH >250U/ml in 60.8%, hypokalemia in 
20.3%, elevated AST in 41.4%, elevated ALT in 32.4%, and elevated D-dimer >500g/L 
in 52.1%. Hydroxychloroquine was administered in 50.3% of patients, azithromycin in 
46.3%, lopinavir/ritonavir in 41%, glucocorticoids in 11.5% and tocilizumab in 8.4%. 
Hospitalization was required in 49.1% of patients (mean stay 9.4 [SD 5.8]) days) and 
ICU admittance in 13%: 37 (11.5%) acute respiratory distress syndrome, 8 (2.5%) 
severe renal failure, 4 (1.2%) pulmonary thromboembolism and 3 (0.9%) sepsis. Overall 
mortality was 5.6%. Primary care home monitoring was made in 17.7% patients and 
51.6% took sick leave. Seventy-two (22.4%) patients reported contact with 
confirmed/suggested COVID 19 at work and 50 (15.5%) in the family.  
DISCUSSION 
This study summarizes the clinical, biological and radiological characteristics of 
patients with COVID-19 disease. Our data show differing findings from other studies 
(2-4), such as more diarrhea, dysgeusia, anosmia, hypokalemia and elevated 
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transaminases and suggests work contacts as a possible source of contagion. In our 
patients, comorbidities were three times higher than in the Chinese 
cohort and were similar to the findings of the New York study (4). The same 
comorbidities were identified, with hypertension and diabetes being the two most 
common. Three months into the pandemic, most countries lack a reliable and available 
diagnostic test. Therefore, determining the clinical, biological and radiological 
characteristics of suspected cases of SARS-CoV-2 infection will be key to initiating 
early treatment and isolation, as will contact tracing from Primary Healthcare. 
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